Patrick Doeblin1, Rene Schilling2, Moritz Wagner3, Reny Luhur4, Alexander Huppertz5, Bernd Hamm6, Matthias Taupitz7, Tahir Durmus8. 1. Department of Cardiology, Charité - Universitätsmedizin Berlin, Charité Campus Benjamin Franklin, Berlin, Germany. Electronic address: Patrick.doeblin@charite.de. 2. Department of Radiology, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Berlin, Germany. Electronic address: rene.schilling@charite.de. 3. Department of Radiology, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Berlin, Germany. Electronic address: moritz.wagner@charite.de. 4. Department of Radiology, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Berlin, Germany. Electronic address: renyluhur@yahoo.com. 5. Department of Radiology, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Berlin, Germany; Imaging Science Institute, Charité, Berlin, Germany. Electronic address: alexander.huppertz@charite.de. 6. Department of Radiology, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Berlin, Germany. Electronic address: bernd.hamm@charite.de. 7. Department of Radiology, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Berlin, Germany. Electronic address: matthias.taupitz@harite.de. 8. Department of Radiology, Charité - Universitätsmedizin Berlin, Charité Campus Mitte, Berlin, Germany. Electronic address: tahir.durmus@charite.de.
Abstract
PURPOSE: To evaluate T1-relaxation times of chronic myocardial infarction (CMI) using gadobutrol and gadopentetate dimeglumine (Gd-DTPA) over time and to determine the optimal imaging window for late enhancement imaging with both contrast agents. MATERIAL AND METHODS:Twelve patients with CMI were prospectively included and examined on a 1.5 T magnetic resonance (MR) system using relaxivity-adjusted doses of gadobutrol (0.15 mmol/kg) and Gd-DTPA (0.2 mmol/kg) in random order. T1-relaxation times of remote myocardium (RM), infarcted myocardium (IM), and left ventricular cavity (LVC) were assessed from short-axis TI scout imaging using the Look-Locker approach and compared intraindividually using a Wilcoxon paired signed-rank test (α<0.05). RESULTS: Within 3 min of contrast agent administration (CA), IM showed significantly lower T1-relaxation times than RM with both contrast agents, indicating beginning cardiac late enhancement. Differences between gadobutrol and Gd-DTPA in T1-relaxation times of IM and RM were statistically not significant through all time points. However, gadobutrol led to significantly higher T1-relaxation times of LVC than Gd-DTPA from 6 to 9 min (220 ± 15 ms vs. 195 ± 30 ms p<0.01) onwards, resulting in a significantly greater ΔT1 of IM to LVC at 9-12 min (-20 ± 35 ms vs. 0 ± 35 ms, p<0.05) and 12-15 min (-25 ± 45 ms vs. -10 ± 60 ms, p<0.05). Using Gd-DTPA, comparable ΔT1 values were reached only after 25-35 min. CONCLUSION: This study indicates good delineation of IM to RM with both contrast agents as early as 3 min after administration. However, we found significant differences in T1 relaxation times with greater ΔT1 IM-LVC using 0.15 mmol/kg gadobutrol compared to 0.20 mmol/kg Gd-DTPA after 9-15 min post-CA suggesting earlier differentiability of IM and LVC using gadobutrol.
RCT Entities:
PURPOSE: To evaluate T1-relaxation times of chronic myocardial infarction (CMI) using gadobutrol and gadopentetate dimeglumine (Gd-DTPA) over time and to determine the optimal imaging window for late enhancement imaging with both contrast agents. MATERIAL AND METHODS: Twelve patients with CMI were prospectively included and examined on a 1.5 T magnetic resonance (MR) system using relaxivity-adjusted doses of gadobutrol (0.15 mmol/kg) and Gd-DTPA (0.2 mmol/kg) in random order. T1-relaxation times of remote myocardium (RM), infarcted myocardium (IM), and left ventricular cavity (LVC) were assessed from short-axis TI scout imaging using the Look-Locker approach and compared intraindividually using a Wilcoxon paired signed-rank test (α<0.05). RESULTS: Within 3 min of contrast agent administration (CA), IM showed significantly lower T1-relaxation times than RM with both contrast agents, indicating beginning cardiac late enhancement. Differences between gadobutrol and Gd-DTPA in T1-relaxation times of IM and RM were statistically not significant through all time points. However, gadobutrol led to significantly higher T1-relaxation times of LVC than Gd-DTPA from 6 to 9 min (220 ± 15 ms vs. 195 ± 30 ms p<0.01) onwards, resulting in a significantly greater ΔT1 of IM to LVC at 9-12 min (-20 ± 35 ms vs. 0 ± 35 ms, p<0.05) and 12-15 min (-25 ± 45 ms vs. -10 ± 60 ms, p<0.05). Using Gd-DTPA, comparable ΔT1 values were reached only after 25-35 min. CONCLUSION: This study indicates good delineation of IM to RM with both contrast agents as early as 3 min after administration. However, we found significant differences in T1 relaxation times with greater ΔT1 IM-LVC using 0.15 mmol/kg gadobutrol compared to 0.20 mmol/kg Gd-DTPA after 9-15 min post-CA suggesting earlier differentiability of IM and LVC using gadobutrol.